We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Delivery of Gene Therapy Difficult in Breast Cancer

Feb 1, 1997
Volume: 
6
Issue: 
2
  • Breast Cancer, Ovarian Cancer

NASHVILLE—In 1996, delivery difficulties were the major barrier to
breast cancer gene therapy, Jeffrey T. Holt, MD, said at a plenary session
of the San Antonio Breast Cancer Symposium.

"Since breast cancer is a largely systemic disease, and we can't
deliver viral vectors systemically, it is difficult to see how we're going
to make any major breakthroughs in breast cancer gene therapy until we
come up with ways to do systemic gene therapy," he said.

In terms of regional gene therapy strategies, two basic protocols have
been initiated in breast cancer—an antisense protocol in breast cancer
pleural effusions and a vector protocol for chest wall recurrences.

"Again, because these treatments are nonsystemic, they are unlikely
to produce any sort of long-term response," said Dr. Holt, associate
professor of cell biology and pathology at the Vanderbilt University School
of Medicine.

Intraperitoneal Administration

Gene therapy is currently a more viable approach in breast cancer's
sister disease, ovarian cancer, he said, because late-stage ovarian cancer
is predominantly an intraperitoneal disease. "If we can decrease the
amount of intraperitoneal disease by a regional gene therapy approach,"
he said, "it is possible that we could have some sort of long-term
benefits to the patient."

He noted several other factors that make ovarian cancer a good target
for gene therapy studies: Retroviral vectors are stable in peritoneal fluid;
there are few competing therapies for late- stage ovarian cancer, which
simplifies patient accrual; and since ovarian cancer can be measured by
laparotomy, the stability of the vector can be assessed.

Finally, he said, there is a constant tumor suppressor defect in the
disease. "Although the BRCA1 gene is mutated in only 5% to 10% of
ovarian cancers, we have found that there is decreased expression of BRCA1
in the vast majority of ovarian cancers," Dr. Holt explained.

In a phase I trial of patients with stage III/IV ovarian cancer, researchers
at Vanderbilt and the University of Washington are currently instilling
into the peritoneal cavity as much as 20 billion vector particles a day
of LXSN-BRCA1, a retroviral vector that expresses BRCA1, in an attempt
to in-crease the level of tumor suppressor.

Twelve patients have been treated so far. They are given four daily
infusions and examined after a month. If their disease has progressed,
treatment is stopped; if they have stable disease or an objective response,
treatment is continued.

Three patients have developed peritonitis, but it appears to be "somewhat
idiosyncratic, not dose related," he said, since it was seen at several
different dose levels. Some patients have had fever and myalgias.

The study has also shown that there is a stable vector in some patients
even with repeat administration, suggesting that immune response is not
significant. "We've only seen antibody formation to retroviral envelope
in one patient to date," Dr. Holt said, "and in this patient,
even though antibody was present, it didn't appear to affect stability."

Stability is affected by complement level within the peritoneal fluid;
patients with stable vector tend to have low complement levels.

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.